Allergan (AGN) Dips as FDA Approves Sientra Silimed-Brand Implants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall St slides as hot CPI data fuels rate-hike bets; chips, banks weigh
- Oil prices steady after gains on Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
Allergan, Inc. (NYSE: AGN) is ticking lower today following a release from competitor Sientra that it has received FDA approval of its portfolio of Silimed-brand silicone breast implants.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta preclinical data shows SRP-1003 reduces DM1 RNA in nucleus
- Daxor shares new heart failure data from HFSA 2026 meeting
- AbbVie Skyrizi shows endoscopic gains in Crohn's disease trial
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
